ZA200707261B - Acylated GLP-1 compounds - Google Patents

Acylated GLP-1 compounds Download PDF

Info

Publication number
ZA200707261B
ZA200707261B ZA200707261A ZA200707261A ZA200707261B ZA 200707261 B ZA200707261 B ZA 200707261B ZA 200707261 A ZA200707261 A ZA 200707261A ZA 200707261 A ZA200707261 A ZA 200707261A ZA 200707261 B ZA200707261 B ZA 200707261B
Authority
ZA
South Africa
Prior art keywords
glp
analog
histidine
peptide
arg
Prior art date
Application number
ZA200707261A
Other languages
English (en)
Inventor
Lau Jesper
Dorwald Florencio Zaragoza
Stephensen Henrik
Bloch Paw
Hansen Thomas Kruse
Madsen Kjeld
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36821525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200707261(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA200707261B publication Critical patent/ZA200707261B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
ZA200707261A 2005-03-18 2007-08-28 Acylated GLP-1 compounds ZA200707261B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05102171 2005-03-18

Publications (1)

Publication Number Publication Date
ZA200707261B true ZA200707261B (en) 2008-05-28

Family

ID=36821525

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200707261A ZA200707261B (en) 2005-03-18 2007-08-28 Acylated GLP-1 compounds

Country Status (24)

Country Link
US (2) US8129343B2 (cg-RX-API-DMAC10.html)
EP (2) EP2322546B1 (cg-RX-API-DMAC10.html)
JP (3) JP5209463B2 (cg-RX-API-DMAC10.html)
KR (1) KR101205272B1 (cg-RX-API-DMAC10.html)
CN (3) CN104017062A (cg-RX-API-DMAC10.html)
AT (1) ATE476446T1 (cg-RX-API-DMAC10.html)
AU (1) AU2006224536B9 (cg-RX-API-DMAC10.html)
BE (1) BE2018C016I2 (cg-RX-API-DMAC10.html)
BR (2) BRPI0607762B8 (cg-RX-API-DMAC10.html)
CA (1) CA2601784C (cg-RX-API-DMAC10.html)
DE (1) DE602006015928D1 (cg-RX-API-DMAC10.html)
DK (2) DK2322546T3 (cg-RX-API-DMAC10.html)
ES (2) ES2557313T3 (cg-RX-API-DMAC10.html)
HU (2) HUE028194T2 (cg-RX-API-DMAC10.html)
IL (1) IL184051A (cg-RX-API-DMAC10.html)
MX (1) MX2007011220A (cg-RX-API-DMAC10.html)
NL (1) NL300936I2 (cg-RX-API-DMAC10.html)
NO (2) NO337946B1 (cg-RX-API-DMAC10.html)
PL (2) PL1863839T3 (cg-RX-API-DMAC10.html)
PT (2) PT2322546E (cg-RX-API-DMAC10.html)
RU (1) RU2434019C3 (cg-RX-API-DMAC10.html)
TW (2) TWI362392B (cg-RX-API-DMAC10.html)
WO (1) WO2006097537A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200707261B (cg-RX-API-DMAC10.html)

Families Citing this family (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US20070203058A1 (en) * 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
AU2006224537A1 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
ES2426445T3 (es) 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) * 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
US20100261637A1 (en) * 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
DK2597103T3 (en) 2007-11-16 2017-02-13 Novo Nordisk As Stable pharmaceutical compositions comprising liraglutide and degludec
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
PT2254906T (pt) 2008-03-18 2017-01-03 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
KR20110007614A (ko) 2008-05-07 2011-01-24 메리온 리서치 Ⅲ 리미티드 ＧｎＲＨ 관련 화합물의 조성물 및 제조 방법
AU2009279090A1 (en) 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
AU2010207721B2 (en) 2009-01-23 2015-03-26 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
EP2440235A1 (en) * 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
JP6006118B2 (ja) * 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
CN103002918B (zh) 2010-01-22 2016-05-04 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
CN102918055B (zh) * 2010-03-26 2017-03-29 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
AU2011247824B2 (en) * 2010-04-27 2014-02-13 Betta Pharmaceuticals Co., Ltd Glucagon-like peptide-1 analogue and use thereof
CN102186881B (zh) * 2010-04-27 2015-04-08 贝达药业股份有限公司 胰高血糖素样肽-1衍生物及其应用
JP5819946B2 (ja) * 2010-05-17 2015-11-24 ベータ ファーマシューティカルズ カンパニー リミテッド 新規のグルカゴン様ペプチド類似体、組成物、および使用方法
WO2012016419A1 (zh) * 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
JP6231386B2 (ja) 2010-11-09 2017-11-15 ノヴォ ノルディスク アー／エス リンカーを有する二重アシル化されたｇｌｐ−１誘導体
RS60321B1 (sr) * 2010-12-16 2020-07-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
WO2012098187A1 (en) 2011-01-19 2012-07-26 Novo Nordisk A/S Glp-1 compositions
WO2012098188A1 (en) 2011-01-19 2012-07-26 Novo Nordisk A/S Glp-1 particles and compositions
EP2691108A1 (en) * 2011-03-28 2014-02-05 Novo Nordisk A/S Novel glucagon analogues
KR101496136B1 (ko) * 2011-03-30 2015-02-26 베타 파머수티컬 컴퍼니 리미티드 글루카곤 유사 펩타이드-1 유사체 및 이의 용도
ES2712945T3 (es) * 2011-04-12 2019-05-16 Novo Nordisk As Derivados de GLP-1 doblemente acilados
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
DK3415139T3 (da) 2011-06-14 2022-06-20 Neurelis Inc Administration af benzodiazepin
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
CN104039822A (zh) 2011-09-06 2014-09-10 诺沃—诺迪斯克有限公司 Glp-1衍生物
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
CN110041399B (zh) 2011-12-29 2023-12-12 诺沃—诺迪斯克有限公司 包含非成蛋白质性的氨基酸的二肽
DK2814844T3 (da) 2012-02-15 2017-11-13 Novo Nordisk As Antistoffer, der binder og blokerer udløsende receptor udtrykt på myeloide celler-1 (trem-1)
ES2690786T3 (es) 2012-02-15 2018-11-22 Novo Nordisk A/S Anticuerpos que se unen a la proteína 1 de reconocimiento de peptidoglicano
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
LT2827885T (lt) 2012-03-22 2018-10-10 Novo Nordisk A/S Glp-1 peptidų kompozicijos ir jų gavimas
CN111494323B (zh) 2012-03-22 2023-03-28 诺和诺德股份有限公司 包含递送剂的组合物及其制备
PT2827885T (pt) * 2012-03-22 2018-11-05 Novo Nordisk As Composições de péptidos glp-1 e sua preparação
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
CN104519902B (zh) 2012-05-08 2017-10-27 诺和诺德股份有限公司 双酰化glp‑1衍生物
EP2846824B1 (en) * 2012-05-08 2017-04-05 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN112142855A (zh) 2012-05-18 2020-12-29 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
HRP20200889T1 (hr) 2012-07-01 2020-09-04 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp-1
CA2878991C (en) 2012-07-23 2021-12-07 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP2908844A1 (en) * 2012-10-17 2015-08-26 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
SI2986313T1 (sl) * 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
RU2671406C2 (ru) 2013-05-02 2018-10-31 Ново Нордиск А/С Пероральная дозированная форма соединений глюкагоноподобного пептида-1
JP6475233B2 (ja) * 2013-06-20 2019-02-27 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
AU2014286234A1 (en) 2013-07-04 2015-12-17 Novo Nordisk A/S Derivatives of GLP-1 like peptides, and uses thereof
US10266577B2 (en) 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
PT3057984T (pt) 2013-10-17 2018-10-24 Boehringer Ingelheim Int Análogos de glucagon acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
JP2017503474A (ja) 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
MX2016005556A (es) 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
CN105934257B (zh) 2013-12-06 2020-10-09 韩捷 用于含氮和羟基的药物的生物可逆引入基团
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
CA2939763A1 (en) 2014-02-18 2015-08-27 Novo Nordisk A/S Stable glucagon analogues and use for treatment of hypoglycaemia
JP6768515B2 (ja) 2014-04-07 2020-10-14 ノヴォ ノルディスク アー／エス 二重アシル化ｇｌｐ−１化合物
TWI668010B (zh) 2014-05-07 2019-08-11 丹麥商諾佛 儂迪克股份有限公司 使用ｇｌｐ－１及抗ｉｌ－２１治療糖尿病
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
CA2955253C (en) 2014-07-17 2023-03-07 Novo Nordisk A/S Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
ES2685987T3 (es) 2014-09-05 2018-10-15 University Of Copenhagen Análogos de péptidos gip
GR20140100479A (el) * 2014-09-23 2016-05-05 Novetide, Ltd., Συνθεση λιραγλουτιδης
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
US11572398B2 (en) 2014-11-27 2023-02-07 Novo Nordisk A/S GLP-1 derivatives and uses thereof
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
MX377044B (es) 2014-12-23 2025-03-07 Novo Nordisk As Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.
JP2018505173A (ja) * 2015-01-29 2018-02-22 ノヴォ ノルディスク アー／エス 錠剤コアと即時放出コーティングとを含む経口ｇｌｐ−１投与用の医薬組成物
ES2975708T3 (es) 2015-01-29 2024-07-12 Novo Nordisk As Comprimidos que comprenden agonista del GLP-1 y recubrimiento entérico
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
AU2016280873A1 (en) * 2015-06-16 2018-01-04 Sun Pharma Advanced Research Company Limited Long acting liraglutide compositions
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CN106554403B (zh) * 2015-09-25 2021-08-31 博瑞生物医药（苏州）股份有限公司 艾塞那肽修饰物及其用途
CN106554409B (zh) * 2015-09-30 2020-04-07 天津药物研究院有限公司 一种长效胰高血糖素样肽-1类似物及其应用
CN106554408A (zh) * 2015-09-30 2017-04-05 天津药物研究院有限公司 长效胰高血糖素样肽-1类似物二聚体及其应用
CN108135962A (zh) 2015-10-07 2018-06-08 塞浦路迈德有限责任公司 用于口服递送肽类药物的药物制剂
CN106928343A (zh) * 2015-12-30 2017-07-07 深圳翰宇药业股份有限公司 索玛鲁肽的制备方法
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
CN107266557B (zh) * 2016-04-06 2020-04-07 天津药物研究院有限公司 一种聚乙二醇修饰的胰高血糖素样肽-1类似物
DK3448416T3 (da) * 2016-04-28 2022-10-03 Novo Nordisk As Semaglutid ved kardiovaskulære tilstande
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
WO2018078112A1 (en) 2016-10-27 2018-05-03 Aarhus Universitet Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
EP3534962B1 (en) 2016-11-07 2020-08-19 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
CN107033234B (zh) * 2017-01-03 2018-06-26 北京凯因科技股份有限公司 酰化的glp-1衍生物
JP2020510028A (ja) * 2017-03-08 2020-04-02 インターシア セラピューティクス，インコーポレイティド 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法
EP3630806B1 (en) 2017-05-31 2024-01-10 The University of Copenhagen Long-acting gip peptide analogues
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
TW201918494A (zh) * 2017-07-19 2019-05-16 丹麥商諾佛 儂迪克股份有限公司 雙功能性化合物
EP4360651A3 (en) * 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
WO2019048660A1 (en) 2017-09-10 2019-03-14 Novo Nordisk A/S MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY
KR102612576B1 (ko) 2017-09-29 2023-12-12 한미약품 주식회사 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법
KR20200069316A (ko) 2017-10-12 2020-06-16 노보 노르디스크 에이/에스 의료 요법에서의 세마글루타이드
CN107881187A (zh) * 2017-11-20 2018-04-06 珠海联邦制药股份有限公司 将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
US11186608B2 (en) 2017-12-21 2021-11-30 Bachem Holding Ag Solid phase synthesis of acylated peptides
HUE063787T2 (hu) 2018-02-02 2024-01-28 Novo Nordisk As Egy GLP-1 agonistát, egy N-(8-(2-hidroxibenzoil)amino) kaprilsav sót és egy síkosítóanyagot tartalmazó szilárd készítmények
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
CN110294800B (zh) * 2018-03-22 2022-03-04 齐鲁制药有限公司 一种索玛鲁肽的制备方法
PE20201343A1 (es) 2018-04-02 2020-11-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y usos de los mismos
WO2019193576A1 (en) 2018-04-05 2019-10-10 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019200594A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN110386974B (zh) * 2018-04-19 2022-12-09 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
MA52483A (fr) 2018-05-04 2021-03-10 Novo Nordisk As Dérivés de gip et leurs utilisations
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
HRP20230929T1 (hr) * 2018-10-26 2023-11-24 Novo Nordisk A/S Stabilni pripravci semaglutida i njihova upotreba
CN109180801B (zh) * 2018-11-01 2021-08-13 汉肽生物医药集团有限公司 一种合成索玛鲁肽的方法
US12187773B2 (en) 2018-12-03 2025-01-07 Antag Therapeutics Aps Modified GIP peptide analogues
WO2020127476A1 (en) 2018-12-19 2020-06-25 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
EP3897582B1 (en) 2018-12-21 2024-09-11 Novo Nordisk A/S Process of spray drying of glp-1 peptide
WO2020152304A1 (en) 2019-01-24 2020-07-30 Novo Nordisk A/S Roller compactor and method of dry granulation using a roller compactor
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
MA55008A (fr) 2019-02-20 2021-12-29 Novo Nordisk As Aminoacyl-arnt synthétases et leurs utilisations
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
WO2020190757A1 (en) 2019-03-15 2020-09-24 Novetide Ltd. Improved processes for the preparation of semaglutide
MY210034A (en) 2019-03-15 2025-08-22 Novo Nordisk As Process for spray drying a glp-1 peptide
CN111748019A (zh) * 2019-03-29 2020-10-09 深圳翰宇药业股份有限公司 一种多肽衍生化合物的合成方法
WO2020201280A1 (en) 2019-04-01 2020-10-08 Novo Nordisk A/S Antibodies directed against liraglutide and use thereof
KR20210149747A (ko) * 2019-04-11 2021-12-09 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 다중-수용체 작용제 및 그의 의학 용도
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
EA202193102A1 (ru) * 2019-05-21 2022-02-17 Медиммун Лимитед Инъекционные совместные составы на основе циклодекстрина, содержащие ингибиторы sglt2 и инкретиновые пептиды
CN114340655A (zh) 2019-09-02 2022-04-12 诺和诺德股份有限公司 生产包含glp-1肽的片剂的方法
BR112022004697A2 (pt) * 2019-09-16 2022-06-14 Biomarin Pharm Inc Variantes de cnp e conjugados das mesmas
CN110590934B (zh) * 2019-09-25 2020-12-08 北京乐普医药科技有限公司 一种glp-1化合物
RS65780B1 (sr) 2019-11-06 2024-08-30 Novo Nordisk As Semaglutid u lečenju alchajmerove demencije
EP3819308A1 (en) 2019-11-07 2021-05-12 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of derivatized amino acids
WO2021089752A1 (en) 2019-11-07 2021-05-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2021105393A1 (en) 2019-11-29 2021-06-03 Novo Nordisk A/S Processes for obtaining stable glp-1 compositions
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
JP2023510218A (ja) * 2019-12-30 2023-03-13 ガン アンド リー ファーマスゥーティカルズ カンパニー リミテッド 長時間作用型ｇｌｐ－１化合物
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
SMT202400344T1 (it) 2020-02-07 2024-11-15 Gasherbrum Bio Inc Agonisti di glp-1 eterociclici
KR102375262B1 (ko) 2020-02-14 2022-03-16 주식회사 지투지바이오 Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물
TWI878456B (zh) 2020-02-18 2025-04-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
EP4132960A2 (en) 2020-04-10 2023-02-15 Fresenius Kabi Oncology Limited An improved process for the preparation of semaglutide side chain
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN115461044B (zh) 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
AR122579A1 (es) * 2020-06-12 2022-09-21 Lilly Co Eli Proceso para preparar un agonista dual glp-1 / glucagón
MX2023000403A (es) 2020-07-22 2023-02-02 Novo Nordisk As Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip).
TW202220973A (zh) 2020-08-06 2022-06-01 美商迦舒布魯姆生物有限公司 雜環glp-1促效劑
CA3190606A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
JP2023541827A (ja) 2020-09-07 2023-10-04 サイプルメド ゲーエムベーハー Ｇｌｐ－１受容体アゴニストの改善された医薬製剤
KR20230083294A (ko) 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법
MX2023004672A (es) 2020-11-06 2023-07-20 Novo Nordisk As Profármacos de péptido tipo glucagón humano 1 (glp-1) y usos de los mismos.
TWI850611B (zh) 2020-12-18 2024-08-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
US20240209056A1 (en) 2021-03-25 2024-06-27 Brightgene Bio-Medical Technology Co., Ltd. Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
TW202304500A (zh) 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
JP2024522196A (ja) 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法
AU2022289247A1 (en) 2021-06-10 2023-12-21 Antag Therapeutics Aps Treatment of obesity and obesity-related disorders
AU2022298186B2 (en) 2021-06-23 2024-10-03 Peptron, Inc. Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof
WO2022268214A1 (zh) 2021-06-25 2022-12-29 甘李药业股份有限公司 Pcsk9抑制剂和glp-1受体激动剂的药物组合
US20250276043A1 (en) * 2021-06-25 2025-09-04 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical Composition Containing GLP-1 Compound
WO2023285347A1 (en) 2021-07-12 2023-01-19 Novo Nordisk A/S Novel fatty acid modified urocortin 2 derivatives and the uses thereof
JP2024527613A (ja) 2021-07-14 2024-07-25 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド 代謝性障害のための融合ポリペプチド
PE20241302A1 (es) 2021-07-15 2024-06-24 Novo Nordisk As Comprimido que comprende una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico
CN116410297A (zh) * 2021-07-19 2023-07-11 内蒙古博睿精创科技有限公司 长效glp-1多肽类似物及其制备方法和应用
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
MX2024002863A (es) 2021-09-08 2024-03-21 Shionogi & Co Medicina para la prevencion y tratamiento de enfermedades vinculadas a la actividad antiobesidad.
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
TWI876242B (zh) 2021-12-13 2025-03-11 丹麥商諾佛 儂迪克股份有限公司 包括環糊精的醫藥調配物
AU2022413318A1 (en) 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
EP4490155A1 (en) 2022-03-09 2025-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2025510741A (ja) 2022-03-21 2025-04-15 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
WO2023187067A1 (en) 2022-03-30 2023-10-05 Novo Nordisk A/S Formulation method
JP2025512832A (ja) 2022-03-30 2025-04-22 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法
CN119255988A (zh) 2022-04-14 2025-01-03 加舒布鲁姆生物公司 杂环glp-1激动剂
JP2025517672A (ja) 2022-05-10 2025-06-10 ノヴォ ノルディスク アー／エス プロドラッグおよびその使用
IL316466A (en) 2022-05-23 2024-12-01 Ascendis Pharma Growth Disorders As Liquid pharmaceutical formulations of cnp compounds
IL318154A (en) 2022-07-05 2025-03-01 G2Gbio Inc A composition containing a microsphere for sustained release of semaglutide pharmaceutical salt and methods for making the same
TW202421654A (zh) 2022-09-28 2024-06-01 丹麥商西蘭製藥公司 治療肥胖之方法
WO2024079043A1 (en) 2022-10-10 2024-04-18 Bachem Holding Ag Method of manufacturing a peptide with a lysine derivative
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與
WO2024128882A1 (ko) 2022-12-16 2024-06-20 주식회사 펩트론 Glp-1 수용체 작용제 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구 및 이의 용도
CN116159027A (zh) * 2022-12-29 2023-05-26 江苏诺泰澳赛诺生物制药股份有限公司 一种司美格鲁肽冻干药物组合物及其制备方法
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
IL323019A (en) 2023-03-06 2025-10-01 Ascendis Pharma As Drug compounds with an albumin-binding moiety
EP4676535A1 (en) 2023-03-06 2026-01-14 Ascendis Pharma A/S Multi-albumin binding compounds
AU2024232757A1 (en) 2023-03-06 2025-08-21 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
AR132255A1 (es) 2023-03-30 2025-06-11 Novo Nordisk As Compuestos de fusión y usos de estos
WO2024234320A1 (zh) * 2023-05-17 2024-11-21 南京知和医药科技有限公司 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
WO2024252366A1 (en) 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
KR20240176455A (ko) 2023-06-15 2024-12-24 노보 노르디스크 에이/에스 시클로덱스트린을 포함하는 약학적 제형
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
WO2025078040A1 (en) 2023-10-09 2025-04-17 Bachem Holding Ag Lysine salt and method of manufacturing a lysine derivative
WO2025077751A1 (zh) * 2023-10-09 2025-04-17 甘李药业股份有限公司 Glp-1肽组合物及其用途
TW202521100A (zh) 2023-11-17 2025-06-01 美商雅沛尼美德公司（德拉瓦州公司） 使用ｇｌｐ－１受體促效劑及第二活性劑之組合治療睡眠呼吸中止之方法及組合物
WO2025114501A1 (en) 2023-11-30 2025-06-05 Novo Nordisk A/S Tri-agonists of the glp-1, gip, and amylin receptors
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
US20250326814A1 (en) 2024-02-06 2025-10-23 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof
EP4684801A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172606A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172605A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684802A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603080A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603079A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
GB202403746D0 (en) 2024-03-15 2024-05-01 New Roger Randal Charles Formulations demonstrating an oral depot effect
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects
WO2026008836A1 (en) 2024-07-05 2026-01-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2026013135A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Albumin-binding reagents
WO2026013136A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Albumin-binding compounds
WO2026013138A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Compounds with improved albumin-binding

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011296A1 (en) 1989-03-20 1990-10-04 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
UA72181C2 (uk) * 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0929576A1 (en) 1996-08-30 1999-07-21 Novo Nordisk A/S Glp-2 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
ATE265224T1 (de) 1998-02-27 2004-05-15 Novo Nordisk As Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden
WO1999043361A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
DE69942307D1 (de) * 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
KR20050037004A (ko) * 1998-12-07 2005-04-20 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Ｇｌｐ-1의 유사체
WO2000069911A1 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
WO2001051071A2 (en) 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
US7186797B2 (en) 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
WO2003058203A2 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
IL164266A0 (en) 2002-04-10 2005-12-18 Lilly Co Eli Treatment of gastroparesis
DE602004025205D1 (de) 2003-02-19 2010-03-11 Ipsen Pharma Glp-1-analoga
HRP20050683A2 (en) 2003-03-19 2006-07-31 Eli Lilly And Company Polyethylene glycol linked glp-1 compounds
BRPI0409976A (pt) * 2003-05-09 2006-05-09 Novo Nordisk As composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
EP1653996A2 (en) * 2003-08-08 2006-05-10 Novo Nordisk Health Care AG Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
US20070203058A1 (en) * 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
EP1696962A2 (en) 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
CA2549582A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 compounds
JP2008507477A (ja) 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
BRPI0517341A (pt) 2004-11-12 2008-10-07 Novo Nordisk As composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1
WO2006097536A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
AU2006224537A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds

Also Published As

Publication number Publication date
AU2006224536B9 (en) 2012-05-10
RU2007134156A (ru) 2009-04-27
PT2322546E (pt) 2016-01-22
BR122019002626A2 (cg-RX-API-DMAC10.html) 2019-04-02
US8536122B2 (en) 2013-09-17
EP2322546B1 (en) 2015-09-30
HUS1800019I1 (hu) 2018-06-28
NO337946B1 (no) 2016-07-18
BE2018C016I2 (cg-RX-API-DMAC10.html) 2025-09-05
US20120295847A1 (en) 2012-11-22
JP2008533105A (ja) 2008-08-21
ES2557313T3 (es) 2016-01-25
DK1863839T3 (da) 2010-11-22
HUE028194T2 (en) 2016-12-28
WO2006097537A3 (en) 2007-01-25
CA2601784A1 (en) 2006-09-21
BRPI0607762B8 (pt) 2021-05-25
NO2018023I1 (cg-RX-API-DMAC10.html) 2018-07-05
RU2434019C3 (ru) 2020-07-20
BRPI0607762A2 (pt) 2010-03-23
IL184051A0 (en) 2007-10-31
US20090156478A1 (en) 2009-06-18
CN104017062A (zh) 2014-09-03
BRPI0607762B1 (pt) 2019-05-07
WO2006097537A2 (en) 2006-09-21
JP4585037B2 (ja) 2010-11-24
MX2007011220A (es) 2007-10-17
JP5209463B2 (ja) 2013-06-12
EP1863839A2 (en) 2007-12-12
EP2322546A1 (en) 2011-05-18
TW200942255A (en) 2009-10-16
KR101205272B1 (ko) 2013-01-11
RU2434019C2 (ru) 2011-11-20
KR20070120089A (ko) 2007-12-21
TWI372629B (en) 2012-09-21
CN101133082B (zh) 2016-01-13
TWI362392B (en) 2012-04-21
NL300936I2 (nl) 2018-08-07
AU2006224536B2 (en) 2012-04-05
EP1863839B1 (en) 2010-08-04
CN104402989A (zh) 2015-03-11
CN101133082A (zh) 2008-02-27
TW200700433A (en) 2007-01-01
PL1863839T3 (pl) 2011-01-31
JP2010116407A (ja) 2010-05-27
PL2322546T3 (pl) 2016-03-31
ES2350051T3 (es) 2011-01-17
NO20075342L (no) 2007-12-18
PT1863839E (pt) 2010-11-10
IL184051A (en) 2015-08-31
DE602006015928D1 (de) 2010-09-16
CA2601784C (en) 2013-12-24
DK2322546T3 (en) 2015-12-14
JP2013063984A (ja) 2013-04-11
US8129343B2 (en) 2012-03-06
AU2006224536A1 (en) 2006-09-21
ATE476446T1 (de) 2010-08-15

Similar Documents

Publication Publication Date Title
EP1863839B1 (en) Acylated glp-1 compounds
EP1863521B1 (en) Extended glp-1 compounds
EP2057189B1 (en) Acylated exendin-4 compounds
ES2672770T3 (es) Derivados del péptido-1 similar al glucagón y su uso farmacéutico
US9657079B2 (en) Truncated GLP-1 derivatives and their therapeutical use